MDGL: Madrigal Pharmaceuticals Inc. Stocks News on October 23, 2024

Madrigal Pharmaceuticals enrols patients in Phase III trial of NASH cirrhosis drug

MDGL

Clinical Trials Arena

a day ago

Madrigal Pharmaceuticals enrols patients in Phase III trial of NASH cirrhosis drug

Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis

MDGL

GlobeNewswire

2 days ago

Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis

Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024

MDGL

GlobeNewswire

5 days ago

Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024

MDGL

Insider Monkey

7 days ago

Madrigal Pharmaceuticals (MDGL): Leading the NASH Treatment Revolution with Rezdiffra

High Growth Tech Stocks To Watch In October 2024

MDGL

Simply Wall St.

14 days ago

High Growth Tech Stocks To Watch In October 2024

Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference

MDGL

GlobeNewswire

21 days ago

Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference

Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development

MDGL

GlobeNewswire

22 days ago

Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development

Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom)

MDGL

GlobeNewswire

23 days ago

Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom)

MDGL

Insider Monkey

a month ago

Is Madrigal Pharmaceuticals, Inc. (MDGL) the Best Guru Stock To Buy Now?

MDGL

MT Newswires

a month ago

Madrigal Pharmaceuticals Insider Sold Shares Worth $1,551,490, According to a Recent SEC Filing

Exploring 3 High Growth Tech Stocks in the United States

MDGL

Simply Wall St.

a month ago

Exploring 3 High Growth Tech Stocks in the United States

Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

MDGL

GlobeNewswire

2 months ago

Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Is Madrigal Pharmaceuticals Stock a Buy?

MDGL

Motley Fool

2 months ago

Is Madrigal Pharmaceuticals Stock a Buy?

John Paulson's Strategic Exits and Key Investments in Q2 2024: Spotlight on Newmark Group Inc

MDGL

GuruFocus.com

2 months ago

John Paulson's Strategic Exits and Key Investments in Q2 2024: Spotlight on Newmark Group Inc

This 1 Setback for Novo Nordisk Is Bullish for Madrigal Pharmaceuticals Stock

MDGL

Motley Fool

2 months ago

This 1 Setback for Novo Nordisk Is Bullish for Madrigal Pharmaceuticals Stock

Madrigal plans to solidify Rezdiffra’s position in MASH despite start being slower than expected

MDGL

Pharmaceutical Technology

2 months ago

Madrigal plans to solidify Rezdiffra’s position in MASH despite start being slower than expected

MDGL

MT Newswires

2 months ago

B. Riley Adjusts Price Target on Madrigal Pharmaceuticals to $194 From $200, Maintains Neutral Rating

MDGL

Thomson Reuters StreetEvents

2 months ago

Q2 2024 Madrigal Pharmaceuticals Inc Earnings Call

Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'

MDGL

Investor's Business Daily

3 months ago

Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'

MDGL

Zacks

3 months ago

Madrigal (MDGL) Tops on Q2 Earnings, NASH Drug Drives Top Line

MDGL

MT Newswires

3 months ago

Madrigal Pharmaceuticals Reports Q2 Revenue as Loss Widens; Shares Gain Pre-Bell

MDGL

Associated Press Finance

3 months ago

Madrigal: Q2 Earnings Snapshot

Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates

MDGL

GlobeNewswire

3 months ago

Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates

Madrigal’s MASH drug launch gets off to a fast start

MDGL

BioPharma Dive

3 months ago

Madrigal’s MASH drug launch gets off to a fast start

Is It Too Late to Buy Madrigal Pharmaceuticals Stock?

MDGL

Motley Fool

3 months ago

Is It Too Late to Buy Madrigal Pharmaceuticals Stock?

Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel

MDGL

GlobeNewswire

3 months ago

Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel

Top Growth Stocks With High Insider Ownership In US For August 2024

MDGL

Simply Wall St.

3 months ago

Top Growth Stocks With High Insider Ownership In US For August 2024

Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024

MDGL

GlobeNewswire

3 months ago

Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024

MDGL

MT Newswires

3 months ago

JMP Securities Raises Price Target on Madrigal Pharmaceuticals to $385 From $381, Maintains Market Outperform Rating

Unveiling Three US Growth Companies With High Insider Ownership

MDGL

Simply Wall St.

4 months ago

Unveiling Three US Growth Companies With High Insider Ownership

Is Madrigal Pharmaceuticals a Millionaire Maker?

MDGL

Motley Fool

4 months ago

Is Madrigal Pharmaceuticals a Millionaire Maker?

MDGL

MT Newswires

4 months ago

Cantor Fitzgerald Starts Madrigal Pharmaceuticals With Neutral Rating

MDGL

Motley Fool

4 months ago

Is Madrigal Pharmaceuticals Stock a Buy?

Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.

MDGL

Motley Fool

4 months ago

Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.

Where Will Madrigal Pharmaceuticals Be in 3 Years?

MDGL

Motley Fool

4 months ago

Where Will Madrigal Pharmaceuticals Be in 3 Years?

Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade

MDGL

Investor's Business Daily

4 months ago

Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade

Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals

MDGL

Motley Fool

4 months ago

Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals

Bang Energy Announces Monumental Partnership with Star Streaming Group AMP

MDGL

PR Newswire

5 months ago

Bang Energy Announces Monumental Partnership with Star Streaming Group AMP

Exclusive-IPOs of Walmart's Flipkart, PhonePe could take couple of years, Walmart exec says

MDGL

Reuters

5 months ago

Exclusive-IPOs of Walmart's Flipkart, PhonePe could take couple of years, Walmart exec says

Broadcom is the 'best AI story' after Nvidia: Analyst

MDGL

Yahoo Finance Video

5 months ago

Broadcom is the 'best AI story' after Nvidia: Analyst

Slapstick platformer Thank Goodness You're Here! arrives August 1

MDGL

Engadget

5 months ago

Slapstick platformer Thank Goodness You're Here! arrives August 1

Earnings Calendar, Analyst Estimates And Stocks To Watch

MDGL

Investor's Business Daily

5 months ago

Earnings Calendar, Analyst Estimates And Stocks To Watch

Gross rescues Germany with last-gasp winner against Greece

MDGL

AFP

5 months ago

Gross rescues Germany with last-gasp winner against Greece

MDGL

Daily Times-Call, Longmont, Colo.

5 months ago

Local News | Longmont Community Justice Partnership marks 30 years of building connections

Tesla shareholders to vote on $56B Musk pay package

MDGL

Yahoo Finance Video

5 months ago

Tesla shareholders to vote on $56B Musk pay package

MDGL

MT Newswires

5 months ago

Madrigal Pharmaceuticals Reports Positive Results in New Analysis of Phase 3 Trial of NASH Drug Rezdiffra

Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress

MDGL

GlobeNewswire

5 months ago

Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress

Madrigal, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH

MDGL

Investor's Business Daily

5 months ago

Madrigal, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH

What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?

MDGL

Benzinga

5 months ago

What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?

Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH

MDGL

Investor's Business Daily

5 months ago

Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH

Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

MDGL

GlobeNewswire

5 months ago

Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress

MDGL

GlobeNewswire

5 months ago

Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress

MDGL

GuruFocus.com

5 months ago

Insider Sale at Madrigal Pharmaceuticals Inc (MDGL): Senior VP, Chief Pharmaceutical ...

MDGL

Motley Fool

5 months ago

Is Madrigal Pharmaceuticals Stock a Buy?

3 High Insider Ownership US Stocks With Up To 55% Revenue Growth

MDGL

Simply Wall St.

5 months ago

3 High Insider Ownership US Stocks With Up To 55% Revenue Growth

MDGL

MT Newswires

5 months ago

Madrigal Pharmaceuticals Insider Sold Shares Worth $4,787,404, According to a Recent SEC Filing

John Paulson's Strategic Moves in Q1 2024 Highlight Madrigal Pharmaceuticals' Prominent Role

MDGL

GuruFocus.com

5 months ago

John Paulson's Strategic Moves in Q1 2024 Highlight Madrigal Pharmaceuticals' Prominent Role

MDGL

MT Newswires

5 months ago

B. Riley Cuts Madrigal Pharmaceuticals' Price Target to $200 From $270, Keeps Neutral Rating

MDGL

MT Newswires

5 months ago

UBS Adjusts Price Target on Madrigal Pharmaceuticals to $411 From $410, Maintains Buy Rating

MDGL

Insider Monkey

5 months ago

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2024 Earnings Call Transcript

MDGL

GuruFocus.com

6 months ago

Madrigal Pharmaceuticals Inc (MDGL) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...

MDGL

MT Newswires

6 months ago

Sector Update: Health Care Stocks Steady Pre-Bell Tuesday

MDGL

GuruFocus.com

6 months ago

Madrigal Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Rezdiffra Launch

MDGL

MT Newswires

6 months ago

Madrigal Pharmaceuticals Q1 Loss Widens; Shares Fall Pre-Bell

MDGL

Associated Press Finance

6 months ago

Madrigal: Q1 Earnings Snapshot

Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

MDGL

GlobeNewswire

6 months ago

Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

Madrigal Statement on the Passing of Dr. Stephen Harrison

MDGL

GlobeNewswire

6 months ago

Madrigal Statement on the Passing of Dr. Stephen Harrison

Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024

MDGL

GlobeNewswire

6 months ago

Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

MDGL

GlobeNewswire

6 months ago

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Latest Insider Selling in April 2024: 10 Stocks to Watch

MDGL

Insider Monkey

6 months ago

Latest Insider Selling in April 2024: 10 Stocks to Watch

Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

MDGL

GlobeNewswire

6 months ago

Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics

MDGL

Motley Fool

7 months ago

Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics

Madrigal Pharmaceuticals Inc Director James Daly Sells 32,489 Shares

MDGL

GuruFocus.com

7 months ago

Madrigal Pharmaceuticals Inc Director James Daly Sells 32,489 Shares

Madrigal Pharmaceuticals Inc Director Richard Levy Sells 11,000 Shares

MDGL

GuruFocus.com

7 months ago

Madrigal Pharmaceuticals Inc Director Richard Levy Sells 11,000 Shares

Madrigal Pharmaceuticals Inc Director Kenneth Bate Sells 32,489 Shares

MDGL

GuruFocus.com

7 months ago

Madrigal Pharmaceuticals Inc Director Kenneth Bate Sells 32,489 Shares

MDGL

GlobeNewswire

7 months ago

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

MDGL

Motley Fool

7 months ago

1 No-Brainer Growth Stock to Buy Now

Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals

MDGL

Motley Fool

7 months ago

Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals

Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval?

MDGL

Motley Fool

7 months ago

Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval?

Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock

MDGL

Motley Fool

7 months ago

Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock

This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy?

MDGL

Motley Fool

7 months ago

This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy?

Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?

MDGL

Motley Fool

7 months ago

Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?

Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering

MDGL

GlobeNewswire

7 months ago

Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering

MDGL

Reuters

7 months ago

UPDATE 1-Madrigal plans $500 million fund raising to prepare for NASH drug launch

MDGL

Reuters

7 months ago

Madrigal commences $500 million public offering of common stock

Madrigal Pharmaceuticals Announces Proposed Public Offering

MDGL

GlobeNewswire

7 months ago

Madrigal Pharmaceuticals Announces Proposed Public Offering

Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark

MDGL

Investor's Business Daily

7 months ago

Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark

Ozempic Can’t Do It All—A Potential New Blockbuster Is a Reminder of That

MDGL

The Wall Street Journal

7 months ago

Ozempic Can’t Do It All—A Potential New Blockbuster Is a Reminder of That

30 Biggest Biotechnology Companies in the World

MDGL

Insider Monkey

7 months ago

30 Biggest Biotechnology Companies in the World

Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?

MDGL

Motley Fool

7 months ago

Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?

Wegovy and Zepbound Cast Shadow Over Madrigal’s Liver Drug

MDGL

Barrons.com

7 months ago

Wegovy and Zepbound Cast Shadow Over Madrigal’s Liver Drug

Madrigal Stock Soars 11% After FDA Approved The First MASH Treatment

MDGL

Investor's Business Daily

7 months ago

Madrigal Stock Soars 11% After FDA Approved The First MASH Treatment

Geron, Madrigal Pharmaceuticals jump on good news from FDA

MDGL

Yahoo Finance Video

7 months ago

Geron, Madrigal Pharmaceuticals jump on good news from FDA

Madrigal Pharmaceuticals Stock Surges After FDA Approves Liver Disease Treatment

MDGL

The Wall Street Journal

7 months ago

Madrigal Pharmaceuticals Stock Surges After FDA Approves Liver Disease Treatment

MDGL

Reuters

7 months ago

US STOCKS-Wall St slides as inflation woes dampen rate-cut bets

Madrigal Can Market the First Drug for Obesity-Scarred Livers. The Stock Soars.

MDGL

Barrons.com

7 months ago

Madrigal Can Market the First Drug for Obesity-Scarred Livers. The Stock Soars.

Madrigal Stock Soars 20% After FDA Approved The First MASH Treatment

MDGL

Investor's Business Daily

7 months ago

Madrigal Stock Soars 20% After FDA Approved The First MASH Treatment

MDGL

Zacks

7 months ago

Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH

Madrigal, FDA approval in hand, outlines plan to sell MASH drug

MDGL

BioPharma Dive

7 months ago

Madrigal, FDA approval in hand, outlines plan to sell MASH drug

Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis

MDGL

GlobeNewswire

7 months ago

Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis

Latest Madrigal Pharmaceuticals Inc. (MDGL) News on October 23, 2024

Share on Social Networks: